Recruiting
Phase 2

Numbing Injection

Sponsor:

Rutgers, The State University of New Jersey

Code:

NCT06734975

Conditions

Vocal Cord Disease

Vocal Cord Polyp

Vocal Cord Cyst

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)

Superior laryngeal nerve block - Placebo (saline)

Study Details

Brief summary:

Patients undergoing surgery on their vocal cord will either receive a numbing injection to their throat or a saline injection during surgery. Symptoms such as how much coughing or pain patients have after surgery, as well as whether patient's voice gets better will be interrogated.

Conditions

Vocal Cord Disease

Vocal Cord Polyp

Vocal Cord Cyst

Study ID

NCT06734975

Start date

Jul 11, 2025

Status verified date

Jan, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient is aged 18 years or older at time of consent
  • Patient has suspected or confirmed benign vocal fold lesion
  • Patient is planning to undergo direct laryngoscopy with excision of the vocal fold lesion
  • Patient is English or Spanish speaking
  • Patient is not pregnant per self report
  • Patient is not incarcerated

Exclusion Criteria:

  • Patient is not 18 years of age or older at consent date
  • Patient does not speak English or Spanish
  • Patient is currently pregnant or plans to become pregnant prior to their study procedure
  • Patient has a laryngeal malignancy or found to find a laryngeal malignancy on final pathology
  • Patient will not be undergoing direct laryngoscopy with excision of lesion
  • Patient is unable to provide consent or complete study activities
  • Patient is incarcerated

Study Design

Enrollment

28 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Superior laryngeal nerve block

Patients will receive a superior laryngeal nerve block consisting of 1 milliliter of 0.25% bupivacaine and milliliter of triamcinolone acetate 40 mg/ml to the neck on the side of the vocal cord lesion during their surgery.

placebo comparator: Placebo

Patients will receive a placebo of 2 milliliter saline injection to the neck on the side of the vocal cord lesion during their surgery.

Interventions

Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension)

Patients will receive a superior laryngeal nerve block consisting of 1 ml of 0.25% bupivacaine and 1mL of triamcinolone acetate 40 mg/ml to the neck on the side of the vocal cord lesion during their surgery.

Superior laryngeal nerve block - Placebo (saline)

Patients will receive a saline placebo of 2mL saline to the neck on the side of the vocal cord lesion during their surgery.

Primary outcome measure

  • Postoperative pain [ Time Frame: 1, 3 and 7 days after surgery ]
  • Postoperative cough [ Time Frame: Follow up appointment 2-4 weeks after surgery ]
  • Postoperative voice outcome [ Time Frame: Postoperative appointment 2-4 weeks after surgery ]

Central Contacts and Locations

Central contacts

Emma Thompson, MD

973-972-2548ert46@njms.rutgers.edu

Locations

Rutgers New Jersey Medical School

Recruiting

Newark, New Jersey, United States, 07103

Contacts

Sandra Oxley

973-972-2548so514@njms.rutgers.edu

More Information

Sponsor

Rutgers, The State University of New Jersey

Last update posted

Jan 15, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Rutgers, The State University of New Jersey on 2026-01-15.